On Tuesday, February 16th at 11:30 AM EST, we will be hosting an event with The Scientist, featuring Dr. James Heath, President of the ISB, and Sean Mackay, IsoPlexis CEO.
The development of drug resistance is an almost universal characteristic of cancers, and is an outstanding challenge in the fields of tumor biology and clinical oncology. While there have been many studies focused on genomic contributions to resistance in cancer cells, recent studies have shown that genetically homogeneous cells can undergo adaptive cell state changes leading to the rapid emergence of drug-tolerant phenotypes. The heterogeneous nature of tumors, coupled with the functional and metabolic changes that accompany adaptive resistance development, suggests that multi-omic, single cell approaches have the potential to provide deep insights into the cell state changes that lead to adaptive resistance, and may provide hypotheses for new therapies and therapy combinations that can prevent resistance development. IsoPlexis’ multi-omic (metabolomics + functional proteomics) energy state application provides a critical and uniquely capable tool for addressing this biology.
Through the use of IsoPlexis’ multi-omic energy state application, independent trajectories to drug tolerance can be revealed, enabling researchers to better develop combination therapies to combat this drug-resistant cell state and prevent drug resistance.
Learn more about this groundbreaking innovative technology and its unique applications in this webinar.
Topics to be discussed:
- Cellular, metabolic, and proteomic changes during drug treatment that lead to resistance
- Using multi-omic approaches to reveal functional adaptations
- Identifying and countering independent trajectories to drug tolerance